BUZZ - JPMorgan downgraded PepsiCo’s rating to "neutral"; share price declined
路透社2026/09/29 08:21September 29 - ** Shares of snack and carbonated beverages giant PepsiCo (PEP.O) fell nearly 1% premarket to $127.5
** JPMorgan downgraded the stock from "Overweight" to "Neutral"; the price target was sharply reduced from $170 to $138, which still represents a 7.3% upside from the previous trading day's closing price
** The brokerage said that based on channel data and recent price increases, after stripping out temporarily boosted demand factors, the North American market could continue to underperform management's expectations
** "Despite a series of measures including adjusting ingredients and packaging, increasing marketing spend, and lowering prices, we believe that the performance of Frito-Lay North America's savory snack business remains lackluster, and the recovery momentum seems to have stalled after Q1 2026," — JPMorgan
** An average of 25 analysts rate the stock as “Hold”; the median price target is $153 — data compiled by LSEG
** As of the previous trading day's close, the stock has fallen about 10.5% so far this year
(To aid non-native English speakers, Reuters provides automated translations of its reports in several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translations, which are provided solely for readers’ convenience. Reuters is not responsible for any harm or loss caused by the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Iovance Biotherapeutics Raises 2026 Revenue Guidance
AstraZeneca (AZN.US) invests in Summit (SMMT.US), gaining positive outlooks from JPMorgan and Citi: Cancer drug strategy awaits validation
Analysts from JPMorgan and Citi have welcomed the deal between AstraZeneca and Summit Therapeutics, stating that it aligns with AstraZeneca's cancer strategy.